ARCH Venture Fund XIII, L.P.

10% owner

ARCH Venture Fund XIII, L.P. (10% owner) filed 2 Form 4 reports as a reporting entity in the trailing twelve months (2 purchases, 0 sales), most often in Lyell Immunopharma, Inc. (LYEL). Across 1 priced purchase filing, the average 21-session return was +0.4% from execution and -6.9% from disclosure (delay-adjusted; derived). The largest single filing was $25.0M of LYEL (2,321,262 sh × $10.77, as filed), executed Nov 4. Data as of Nov 8 2026.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

+0.4%

avg across 1 priced filings

Delay-adjustediThe same average, entered at disclosure dates

-6.9%

same 1 filings, from disclosure

Filings, ttm

2 buys · 0 sells

Median delay

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$37.5M

shares × price, as filed

Last traded

Nov 4

Filed Nov 5

Median ADV $2.9M across their filed names

50% of their measured filings could not be priced (delisted or unquoted names). The returns above cover only what still trades.

Open performance→

Volume by month

Buys $37.5M Sells $0

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 2 filings

Sector per market data · by filing · past 12 months

Most traded names

LYEL

Lyell Immunopharma, Inc. LYEL · 2 buys · 0 sells 2 filings

Recent filings

LYELPURCHASE Lyell Immunopharma, Inc. View filing → $25.0M
2,321,262 sh × $10.77
Exec Nov 4
Filed Nov 5 · 5:34 PM ET LYELPURCHASE Lyell Immunopharma, Inc. View filing → $12.5M
488,090 sh × $25.61
Exec Mar 6
Filed Mar 9 · 4:34 PM ET